An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy.
Despite hopes for attack of multiple viral targets, the licensed agents now in use are all of one type: the nucleoside analogue reverse transcriptase inhibitors, of which four, including zidovudine, are available, with a fifth likely to follow. Clinicians and patients are still struggling to learn how best to employ them; but even now, the available trial results can be distilled into rational management plans.